Volume Spike Investor

ARYx Therapeutics Inc. (Nasdaq: ARYX) shares are down about 51 percent to $2.05 in premarket trading of about 60,000 shares after the company’s experimental anticoagulant Tecarfarin failed to meet its endpoint in a late-stage study. The study hoped to show Tecarfarin worked better than the competing drug Warfarin, but Warfarin did better than anticipated among the 612 patients studied. — Mike Tarsala